Could a daily aspirin save lives after pneumonia in the elderly?
NCT ID NCT06774846
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether taking a low-dose aspirin (100 mg) every day for 90 days can reduce deaths and heart-related complications in people aged 75 and older who are hospitalized with pneumonia. Researchers will compare aspirin against a placebo in 600 participants across multiple hospitals. The goal is to see if this simple, low-cost treatment can improve long-term survival after pneumonia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin (acetylsalicylic acid) 100 mg daily
What this could lead to
If it works, this could offer a simple, cheap way to lower the risk of death and heart complications after pneumonia in older adults.
What could go wrong
This is a large phase 3 trial, but aspirin can cause bleeding, and the benefit may be small or absent. Results may not apply to all elderly patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••